文献速递慢性肾脏病肾血管病与高血压遗传性与小管间质肾病

无肾脏病时循环FGF23升高不增加心血管疾病风险

The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk.
PubMed 文献 · Kidney Int · 2018-05-05

本研究利用新型小鼠X连锁低磷血症模型PhexC733RMhda,探究无肾损伤时高循环FGF23是否诱发心血管疾病。结果显示,27周龄小鼠无左心室肥厚、心功能异常、炎症或血压、肾小球滤过率改变,提示单纯高FGF23在无肾损伤及正常/高磷条件下不足以导致心血管疾病。

要点

  • 无肾损伤时高FGF23不引起左心室肥厚或心功能改变。
  • 高FGF23未激活心脏和肝脏钙调磷酸酶/NFAT通路或炎症。
  • 血压、肾小球滤过率和尿素清除率在基因型间无差异。

核心结论

  • 单纯循环FGF23升高在无肾损伤且血磷正常或升高时不足以导致心血管疾病。

研究设计与样本

  • 使用新型小鼠X连锁低磷血症模型PhexC733RMhda,携带氨基酸替换p.Cys733Arg,在27周龄评估心血管表型。

主要发现

  • 小鼠表现出高FGF23、低磷血症、正常血钙、低/正常维生素D、甲状旁腺功能亢进及低循环可溶性αKlotho。
  • 27周龄时超声心动图未见左心室肥厚和心功能改变。
  • 心脏和肝脏钙调磷酸酶/NFAT通路未激活,无组织及全身炎症迹象。
  • 血压、肾小球滤过率和尿素清除率在基因型间相似。

临床怎么用

  • 在肾内科评估心血管风险时,需结合肾功能和血磷水平解读FGF23升高的意义。
  • 无肾脏病的高FGF23状态(如X连锁低磷血症)可能不独立增加心血管风险。

局限性

  • 研究为小鼠模型,结论外推至人类需谨慎。
  • 未报告样本量、具体P值或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High circulating fibroblast growth factor 23 (FGF23) levels are probably a major risk factor for cardiovascular disease in chronic kidney disease. FGF23 interacts with the receptor FGFR4 in cardiomyocytes inducing left ventricular hypertrophy. Moreover, in the liver FGF23 via FGFR4 increases the risk of inflammation which is also found in chronic kidney disease. In contrast, X-linked hypophosphatemia is characterized by high FGF23 circulating levels due to loss of function mutations of the phosphate-regulating gene with homologies to an endopeptidase on the X chromosome (PHEX), but is not characterized by high cardiovascular morbidity. Here we used a novel murine X-linked hypophosphatemia model, the PhexC733RMhda mouse line, bearing an amino acid substitution (p.Cys733Arg) to test whether high circulating FGF23 in the absence of renal injury would trigger cardiovascular disease. As X-linked hypophosphatemia patient mimics, these mice show high FGF23 levels, hypophosphatemia, normocalcemia, and low/normal vitamin D levels. Moreover, these mice show hyperparathyroidism and low circulating soluble αKlotho levels. At the age of 27 weeks we found no left ventricular hypertrophy and no alteration of cardiac function as assessed by echocardiography. These mice also showed no activation of the calcineurin/NFAT pathway in heart and liver and no tissue and systemic signs of inflammation. Importantly, blood pressure, glomerular filtration rate and urea clearance were similar between genotypes. Thus, the presence of high circulating FGF23 levels alone in the absence of renal impairment and normal/high phosphate levels is not sufficient to cause cardiovascular disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Pastor-Arroyo EM, Gehring N, Krudewig C, et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int. 2018. PMID: 29735309. doi:10.1016/j.kint.2018.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。